XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.2

License Agreements - MorphoSys (Details) $ in Thousands, shares in Millions	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2024 USD ($) shares	Feb. 05, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
License Agreements
Long term equity investments			$ 29,668		$ 29,668		$ 187,716	[1]
Realized and unrealized gain on equity investments			39,241	$ 41,811	139,188	$ 36,493
(Profit) and loss sharing under collaboration agreements			0	(549)	(1,025)	(1,911)
Research and development			1,138,380	400,750	1,567,640	807,391
MorphoSys AG
License Agreements
Shares divested (in shares) | shares	3.6
Realized and unrealized gain on equity investments			800
Unrealized gain (loss) on long term investments				$ 12,700
ADSs
License Agreements
Share conversion	0.25
MorphoSys AG
License Agreements
Proceeds from sale of equity securities, FV-NI	$ 66,600
MorphoSys AG
License Agreements
Long term equity investments			0		0		35,900
Realized and unrealized gain on equity investments					30,700
Unrealized gain (loss) on long term investments						$ 14,100
Profit (loss) sharing ratio		50.00%		50.00%		50.00%
Research and development		$ 10,700		$ 20,300		$ 45,500
Accrued and other liabilities			$ 0		$ 0		$ 18,800
MorphoSys AG | Tafasitamab Product and Service | UNITED STATES
License Agreements
(Profit) and loss sharing under collaboration agreements		$ (1,000)		$ (500)		$ (1,900)
MorphoSys AG | MorphoSys AG
License Agreements
Funding of future development costs (as a percent)					45.00%
MorphoSys AG | Incyte
License Agreements
Funding of future development costs (as a percent)		55.00%		55.00%		55.00%
[1] The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date.

X

- Definition

Ratio of sharing profit and losses under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	incy_CollaborationAgreementProfitLossSharingRatio
Namespace Prefix:	incy_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration Loss (Profit) Sharing Expense

+ References

No definition available.

+ Details

Name:	incy_CollaborationLossProfitSharingExpense
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the percentage of future global development costs funded under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
Namespace Prefix:	incy_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted.

+ References

No definition available.

+ Details

Name:	incy_SubsidiaryStockConversionRatio
Namespace Prefix:	incy_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.

+ References

No definition available.

+ Details

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A

+ Details

Name:	us-gaap_EquitySecuritiesFVNINoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 321
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479536/321-10-50-4

+ Details

Name:	us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 321
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479536/321-10-50-4

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-19

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-SubTopic 10
-Topic 321
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479567/321-10-45-1

+ Details

Name:	us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MorphosysAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MorphoSysAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_MorphoSysAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_TafasitamabProductAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=incy_MorphoSysAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=incy_IncyteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: